Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced positive topline results from its pivotal Phase 3 APPROACH trial evaluating HLP003 (deuterated psilocin) as an adjunctive treatment for adults with major depressive disorder. The randomized, double-blind, placebo-controlled study enrolled 222 participants and achieved statistically significant improvements across its primary, key secondary and other secondary endpoints, according to the company's announcement.
At the primary six-week endpoint, HLP003 produced a 19.5-point reduction from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS), compared with 11.9 points for placebo, representing a 7.6-point difference (p<0.0001). Significant improvements were observed as early as Day 2, with treatment benefits maintained through Week 12, when the placebo-adjusted difference was 7.0 points (p<0.0001). HLP003 also demonstrated statistically significant improvements in response and remission rates, with 50.9% of treated participants achieving remission at Week 6 compared with 18.2% receiving placebo. The treatment was generally well tolerated, with most adverse events mild to moderate and transient, although three treatment-related serious adverse events were reported. No new safety signals were identified.
The results matter because major depressive disorder remains a leading cause of disability worldwide, and many patients fail to achieve adequate response with existing therapies. A novel mechanism with rapid onset and durable benefit could reshape treatment paradigms. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, a status designed to expedite development and review of drugs for serious conditions. The APPROACH trial is the first of three studies in the company's PARADIGM Phase 3 program, which also includes the ongoing EMBRACE pivotal trial and EXTEND long-term extension study. Helus Pharma expects to report topline results from EMBRACE in the fourth quarter of 2027 as it advances HLP003 toward potential regulatory approval and commercialization. For investors, the readout de-risks the program ahead of the remaining trials, though the path to market still includes regulatory review and the need to replicate these findings in EMBRACE.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is a clinical-stage pharmaceutical company committed to helping minds heal by developing proprietary novel serotonergic agonists (NSAs), synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company's NSAs are intended to address the large unmet need for people who suffer from depression, anxiety and other mental health conditions. Helus Pharma is also developing HLP004 in Phase 2 for generalized anxiety disorder and operates in Canada, the United States, the United Kingdom and Ireland. For more details, see https://ibn.fm/IloYS and visit www.helus.com.
The announcement was disseminated by NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NNW is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution and corporate communications solutions. Full terms of use and disclaimers are available at https://www.NetworkNewsWire.com/Disclaimer.


